Scandion Oncology A/S (ST:SCOL) — Market Cap & Net Worth
Market Cap & Net Worth: Scandion Oncology A/S (SCOL)
Scandion Oncology A/S (ST:SCOL) has a market capitalization of $103.58K (Skr962.52K) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #31280 globally and #746 in its home market, demonstrating a -19.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scandion Oncology A/S's stock price Skr0.00 by its total outstanding shares 234762000 (234.76 Million). Review Scandion Oncology A/S (SCOL) total liabilities to assess the company's total debt and financial obligations.
Scandion Oncology A/S Market Cap History: 2021 to 2025
Scandion Oncology A/S's market capitalization history from 2021 to 2025. Data shows change from $312.77 Million to $103.58K (-84.99% CAGR).
Scandion Oncology A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scandion Oncology A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SCOL by Market Capitalization
Companies near Scandion Oncology A/S in the global market cap rankings as of June 19, 2026.
Key companies related to Scandion Oncology A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Scandion Oncology A/S Historical Marketcap From 2021 to 2025
Between 2021 and today, Scandion Oncology A/S's market cap moved from $312.77 Million to $ 103.58K, with a yearly change of -84.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Skr103.58K | -94.50% |
| 2024 | Skr1.88 Million | -98.14% |
| 2023 | Skr100.93 Million | +42.68% |
| 2022 | Skr70.74 Million | -77.38% |
| 2021 | Skr312.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Scandion Oncology A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.58K USD |
| MoneyControl | $103.58K USD |
| MarketWatch | $103.58K USD |
| marketcap.company | $103.58K USD |
| Reuters | $103.58K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more